Claritas Pharmaceuticals, Inc.
CLAZF · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Market Cap | $13 | $417 | $298 | $1,145 |
| - Cash | $5 | $32 | $227 | $3,686 |
| + Debt | $925 | $736 | $246 | $2,868 |
| Enterprise Value | $933 | $1,121 | $317 | $327 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,792 | -$16,723 | $18,136 | -$15,441 |
| % Margin | – | – | – | – |
| Net Income | $4,210 | -$21,212 | $6,935 | -$31,863 |
| % Margin | – | – | – | – |
| EPS Diluted | 0.16 | -1 | 0.64 | -5.2 |
| % Growth | 116% | -256.3% | 112.3% | – |
| Operating Cash Flow | -$309 | -$6,483 | -$4,848 | -$5,561 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$309 | -$6,483 | -$4,848 | -$5,561 |